Cost-Effectiveness of Hysterectomy, First- and Second-Generation Endometrial Ablation, and Levonorgestrel-Releasing Device for Treatment of Heavy Menstrual Bleeding: A Systematic Review Publisher Pubmed



Niaraees Zavare AS¹ ; Rezapour A² ; Souresrafil A³ ; Rouholamin S⁴ ; Nassiri S⁵ Show Affiliations
Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2025

Abstract

Objectives: This study aims to provide a clear understanding of the relative economic evaluation of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing intrauterine device for treatment of heavy menstrual bleeding. Methods: A comprehensive search was conducted without restrictions until October 5, 2023, across databases including PubMed, EMBASE, Scopus, Cochrane, and others. The review included studies using full economic evaluation methods to compare treatments, excluding review articles, editorials, abstracts, and non-English articles. Methodological quality of included studies was assessed using the QHES checklist and analyzed with Incremental Cost-Effectiveness Ratios. Results: Out of 156 articles assessed for full-text evaluations, 23 publications were selected for qualitative analysis. Two studies deemed to be of low quality were excluded from the final analysis, while the majority of studies showcased high quality. The findings presented diverse perspectives on the most cost-effective treatment, with LNG-IUD frequently emerging as the preferred choice. Conclusion: There are diverse methodologies in economic evaluations, impacting reported health economic outcomes due to varying perspectives, time horizons, and modeling approaches. The review highlighted the need for further research to establish optimal HMB treatment strategies and to guide healthcare resource allocation. Registration: PROSPERO (CRD42024530176). © 2024 Informa UK Limited, trading as Taylor & Francis Group.